GSP Crop Science Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

The transcript does not explicitly mention specific current or future capex or strategic investments. However, based on the information provided: - The company has invested in backward integration manufacturing plants (e.g., at Dahej, Saykha) to reduce import dependency, which led to increased depreciation. - Ongoing R&D pipeline includes technical and formulation development with plans to launch 1-2 technical products and 2-3 patented formulations annually over the next 4-5 years, indicating continued investment in product development. - Capacity utilization notes suggest the possibility of product mix optimization within existing technical plants, and formulation capacity has ample headroom, implying no imminent major capacity expansions. - No additional land or non-core asset sales planned, indicating focused operational investment rather than asset divestiture. - IPO proceeds were primarily used for loan repayment, with no mention of significant remaining funds allocated for capex. Overall, focus appears on R&D and optimizing existing manufacturing assets rather than large new capital investments.

The transcript does not explicitly mention the current or expected order book or pending orders with precise figures. However, relevant insights related to demand and sales outlook include: - Domestic demand is supportive with anticipated growth on track for Q2, especially due to a good monsoon. - Export demand, particularly from Brazil and Latin America, has experienced some delays due to pricing volatility and liquidity issues but is expected to pick up in H2 starting September. - In Latin America, GSP is cautious but focusing on established B2B customers and expanding with second-tier distributors. - The company anticipates demand to kick in for the Kharif season starting October, with good demand growth expected in insecticides and fungicides. - Overall, there are no material supply constraints currently, suggesting the order fulfillment capacity is healthy. No specific numeric figures regarding order book or pending orders are disclosed.